Back to search results

Y-90 Treatment Response for Liver Cancer Using Ultrasound

This study is looking at how well a special type of ultrasound, called contrast-enhanced ultrasound (CEUS), can show if treatment for liver cancer (Hepatocellular Carcinoma or HCC) is working. The treatment being studied is called transarterial radioembolization (TARE). Researchers will use two contrast agents, Lumason and Sonazoid, during the ultrasound to see how the tumor responds after TARE. They want to see if CEUS can accurately tell if the tumor is still active 1-2 months and 3-6 months after treatment. You may be able to join if you are at least 18 years old, have HCC that can be seen on ultrasound, and are scheduled for TARE for the first time. The study aims to enroll 30 participants.

Study design
This is an interventional study with an enrollment goal of 30 participants. It is not specified if it's randomized or blinded.
What's involved
You will have baseline ultrasound imaging, followed by CEUS using Lumason and Sonazoid. You will be monitored for at least 30 minutes after the exam.
Compensation
Not stated in the trial record.
Follow-up
Your tumor viability will be assessed using CEUS at 1-2 months and again at 3-6 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07145801

Y-90 Treatment Response Using Transarterial Radioembolization

Recruiting
PHASE2Ages 18+InterventionalDiagnostic
Thomas Jefferson University
~30 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:LumasonSonazoid

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Tumor viability on contrast enhanced ultrasound using a blood pooling contrast agent
Measured over 1-2 months post treatment
+1 more outcome measured

Conditions

HCC
Hepatocellular Carcinoma
Liver Cancer
Hepatic Neoplasm
Primary Liver Cancer
Liver Neoplasm

Explore related trials

Hepatocellular Carcinoma

NCT07145801

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvaniastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • John Eisenbrey, PhD · PRINCIPAL_INVESTIGATOR · Thomas Jefferson University

Who to contact

Site Public Contact
[email protected]
215-600-9151
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Scheduled for TARE therapy of a treatment naïve HCC visible on ultrasound.
Be at least 18 years of age.
Be medically stable.
If a female of child-bearing age, must have a negative pregnancy test.
Have signed Informed Consent to participate in the study.

Exclusion

Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable.
Patients with known sensitivities to the components of Lumason.
Patients with known sensitivities to the components of Sonazoid.

What this trial measures

  • Tumor viability on contrast enhanced ultrasound using a blood pooling contrast agent1-2 months post treatment

    Viability of tumor assessed by three radiologists using contrast-enhanced ultrasound

  • Tumor viability on contrast enhanced ultrasound using a blood pooling contrast agent3-6 months post treatment

    Viability of tumor assessed by three radiologists using contrast-enhanced ultrasound